CSTF2T

Across TCGA pan-cancer cohorts, CSTF2T mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated CSTF2T data layer compared with 26 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher CSTF2T mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated CSTF2T expression acts as an unfavorable survival marker, although some lineages such as PDAC show a favorable association.

CCRCC, PDAC, and LUAD are the cancer types where CSTF2T mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Median	IV	0.451	1.000	.016	12	view →
PDAC	DFS	Tertile	IV	0.741	0.199	.024	3	view →
LUAD	DFS	Tertile	II,III,IV	0.815	0.855	.045	1	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

CSTF2T–CCRCC (OS)

Open the CCRCC breakdown →